Karyopharm Therapeutics reported $35.07M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Abbott USD 13.01B 423M Sep/2026
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Incyte USD 1.56B 110M Sep/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.52B 112M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Takeda JPY 1.19T 32.9B Sep/2026
Tectonic Therapeutic USD 0 0 Dec/2024
TG Therapeutics USD 259.94M 19.6M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026